Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study

Authors

Brad S. Kahl, Washington University School of Medicine in St. Louis
et al.

Journal

Haematologica

Publication Date

2017

Volume

102

Issue

4

Inclusive Pages

e156-e159

Document Type

Open Access Publication

DOI

10.3324/haematol.2016.151738

Rights and Permissions

Brad S Kahl, et al (2017) Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica 102(4): e156-e159. doi: 10.3324/haematol.2016.151738. Obtained from the Haematolgica Journal website http://www.haematologica.org.

Recommended Citation

Kahl, Brad S. and et al., "Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study." Haematologica. 102, 4. e156-e159. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5928